Establishing Amyloid PET Imaging Biomarkers: Ongoing Efforts

REFERENCES

1. 1.↵
   2. Wahl RL,
   3. Zasadny K,
   4. Helvie M, et al

   . Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101–11

   Abstract/FREE Full Text
2. 2.↵
   2. Minoshima S,
   3. Frey KA,
   4. Koeppe RA, et al

   . A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238–48

   Abstract/FREE Full Text
3. 3.↵
   2. Nayate AP,
   3. Dubroff JG,
   4. Schmitt JE, et al

   ; Alzheimer's Disease Neuroimaging Initiative. Use of standardized uptake value ratios decreases interreader variability of [18F] florbetapir PET brain scan interpretation. AJNR Am J Neuroradiol 2015;36:1237–44

   Abstract/FREE Full Text
4. 4.↵
   2. Lopresti BJ,
   3. Klunk WE,
   4. Mathis CA, et al

   . Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005;46:1959–72

   Abstract/FREE Full Text
5. 5.↵
   2. Landau SM,
   3. Thomas BA,
   4. Thurfjell L, et al

   ; Alzheimer's Disease Neuroimaging Initiative. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 2014;41:1398–407

   CrossRefPubMed
6. 6.↵
   2. Klunk WE,
   3. Koeppe RA,
   4. Price JC, et al

   . The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 2015;11:1–15.e1–4

   CrossRefPubMed